ARTICLE | Management Tracks
BI’s Fine becomes president of R&D at EvolveImmune
Plus Sallah joins Genespire as CMO, and updates from Kinaset, Andera, Ariceum and more
July 8, 2022 12:35 AM UTC
Connecticut-based immuno-oncology play EvolveImmune Therapeutics Inc. hired Jay Fine as president of R&D. Fine joins from Boehringer Ingelheim GmbH, where he was SVP and global therapeutic area head for immunology and respiratory diseases. He was previously at Schering-Plough Corp., now a part of Merck & Co. Inc. (NYSE:MRK), for 18 years.
Ventus Therapeutics Inc. promoted CBO Daniel Koerwer to COO. Koerwer joined Ventus in 2019 from Arrakis Therapeutics Inc. where he was CBO. Ventus is developing small molecules using structural biology and its computational platform...